NeoGenomics to Participate in Upcoming Investor Conferences
Get Alerts NEO Hot Sheet
Join SI Premium – FREE
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:
-
TD Cowen 46th Annual Health Care Conference in Boston, MA
Fireside chat on Tuesday, March 3, at 1:10 pm ET, accessible here
-
Leerink Global Healthcare Conference in Miami, FL
Fireside chat on Tuesday, March 10, at 4:20 pm ET, accessible here
Live and archived webcasts of the sessions may be viewed on the Investor Relations section of the Company’s website at ir.neogenomics.com.
About NeoGenomics
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218686355/en/
Investor Contact
Kendra Webster
[email protected]
Media Contact
Andrea Sampson
[email protected]
Source: NeoGenomics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Discover Network and Diners Club International Announce Strategic Payments Partnership with Merlin Entertainments to Enhance Visitor Experience
- Clean Food Group and Raven Botanicals Partner for World-First Commercial Launch of Fermentation-Derived CLEANOil™ in Skincare
- Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share